This post was originally published on this site
InvestingPro users got all the news first and reacted in real time! Join now for under $9 a month for limited time only and never miss out on another buying opportunity.
Coinbase Global (NASDAQ:COIN) saw its shares surge over 12% pre-market today following the announcement of Q4 earnings that exceeded Wall Street’s expectations, as the approval of spot-bitcoin exchange-traded funds boosted activity on the crypto exchange platform.
Coinbase reported Q4 EPS of $1.04, significantly outperforming the analyst forecast of $1.00. The company’s revenue for the quarter reached $953.8 million, surpassing the expected $826.69M. Total transaction revenue jumped 64% year-on-year to $529.3M in Q4, while subscription and services revenue climbed 33% to $375.4M.
Following the results, JPMorgan raised its rating on Coinbase Global from Underweight to Neutral, setting a new price target of $80.00.
But how would you know enough to buy it ahead of the report?
This is where our predictive AI tool, ProPicks, comes into play.
Leveraging a comprehensive analysis that incorporates historical market data and state-of-the-art fundamental analysis, ProPicks successfully identifies such opportunities as part of its six strategies, offering its users an incredible start to the month.
Airbnb (NASDAQ:ABNB) exceeded expectations in its Q4 revenues, fueled by sustained strong demand for travel, which boosted bookings. The company reported a Q4 revenue of $2.2 billion, surpassing the expected $2.16B. This outperformance was attributed to a 12% year-over-year increase in bookings for nights and experiences, leading to a 15% rise in gross booking value to $15.5B. Q4 EPS came in at ($0.55), compared to the analysts’ estimate of $0.65.
For Q1/24, the company expects revenue in the range of $2.03-$2.07B, versus the consensus of $2.02B.
Additionally, Airbnb announced a new share repurchase program, authorizing the buyback of up to $6B of its Class A common stock.
Despite these positive results, DA Davidson downgraded Airbnb from Buy to Neutral, setting a price target of $145. The downgrade reflects a shift towards a more “neutral to normalizing” growth profile for Airbnb.
Coca-Cola (NYSE:KO) announced its Q4 earnings, matching analyst expectations with an EPS of $0.49. The company’s revenue for the quarter was $10.8B, exceeding the consensus estimate of $10.67B, thanks to increased prices and strong demand for its range of juices, energy drinks, and sodas.
Looking forward, Coca-Cola anticipates achieving an adjusted organic revenue growth of 6% to 7% for the full year, surpassing the consensus forecast of 5.9%.
Furthermore, the company hiked its annual dividend by 5.4% to $0.485 per share, with an annual yield of 0.8%.
Cisco Systems (NASDAQ:CSCO) outperformed analyst expectations for Q2, reporting an EPS of $0.87, which is higher than the predicted $0.84. The company’s revenue reached $12.8B, above the consensus estimate of $12.71B.
However, Cisco Systems revised its full-year outlook downwards and announced a workforce reduction of approximately 5% as part of a comprehensive restructuring plan. This news contributed to a decline in Cisco’s share price of more than 2% yesterday.
For Q3, Cisco anticipates an EPS between $0.84 and $0.86, which falls short of the expected $0.92. The company also forecasts Q3 revenue to be between $12.1B and $12.3B, below the anticipated $13.09 billion.
Looking at the full fiscal year 2024, Cisco projects an EPS ranging from $3.68 to $3.74, compared to the consensus estimate of $3.86. The company’s expected revenue for 2024 is between $51.5B and $52.5B, which is less than the consensus forecast of $54.3B.
Furthermore, Cisco Systems raised its quarterly dividend by 2.6% to $0.40 per share, or $1.6 annualized, with an annual yield of 3.2%.
Biogen (NASDAQ:BIIB) shares fell more than 7% on Tuesday after the company reported earnings for its latest quarter, missing the consensus profit and revenue estimate.
The biotechnology firm reported Q4 EPS of $2.95, worse than the analyst estimate of $3.18. Revenue for the quarter came in at $2.4B, compared to the consensus estimate of $2.47B. The company said its EPS during the quarter was negatively impacted by $0.35 related to previously disclosed closeout costs for Aduhelm.
For fiscal 2024, the company expects EPS between $15 and $16, compared to the consensus of $15.64, while it anticipates total revenue to decline by a low- to mid-single digit percentage vs. 2023 and expects core pharmaceutical revenue to be flat vs. 2023.
Take your investing game to the next level in 2024 with ProPicks
Institutions and billionaire investors worldwide are already well ahead of the game when it comes to AI-powered investing, extensively using, customizing, and developing it to bulk up their returns and minimize losses.
Now, InvestingPro users can do just the same from the comfort of their own homes with our new flagship AI-powered stock-picking tool: ProPicks.
With our six strategies, including the flagship “Tech Titans”, which outperformed the market by a lofty 952% over the last decade, investors have the best selection of stocks in the market at the tip of their fingers every month.
Subscribe here for under $9 a month and never miss a bull market again!
